BMS 605541

Key Product Details

Product Description

BMS 605541 is a potent ATP-competitive VEGFR-2 inhibitor (IC₅₀ = 23 nM). Shows >10-fold selectivity for VEGFR-2 over VEGFR-1. Displays antitumor properties in human lung and colon tumor xenograft models. Orally bioavailable in rodents.

Product Specifications for BMS 605541

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for BMS 605541

The following data is based on the product molecular weight 401.43.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.49 mL	12.46 mL	24.91 mL
5 mM	0.50 mL	2.49 mL	4.98 mL
10 mM	0.25 mL	1.25 mL	2.49 mL
50 mM	0.05 mL	0.25 mL	0.50 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Borzilleri Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2. J.Med.Chem 2006 PMID: 16789733

Product Documents for BMS 605541